

DISCUSSIONS WITH LEADERS

- 1167** **A Life Study in Academic Leadership: A Conversation Between Carolyn C. Meltzer and Hossein Jadvar**
Carolyn C. Meltzer and Hossein Jadvar

STATE OF THE ART

- 1171** **The Use of Tau PET to Stage Alzheimer Disease According to the Braak Staging Framework**
Arthur C. Macedo, Cécile Tissot, Joseph Therriault, Stijn Servaes, Yi-Ting Wang, Jaime Fernandez-Arias, Nesrine Rahmouni, Firoza Z. Lussier, Marie Vermeiren, Gleb Bezgin, et al.

FOCUS ON MOLECULAR IMAGING

- 1179** **Molecular Imaging, Radiochemistry, and Environmental Pollutants**
Samantha Delaney, Joni Sebastiano, Brian M. Zeglis, and Outi M. Keinänen

ONCOLOGY

Clinical

- 1185** **Evaluation of [⁶⁸Ga]-DOTATOC PET/MRI in Patients with Meningioma of the Subcranial and Intraorbital Space**
Aleksandar Milosevic, Hanna Styczen, Johannes Grueneisen, Yan Li, Manuel Weber, Wolfgang P. Fendler, Julian Kirchner, Philipp Damman, Karsten Wrede, Lazaros Lazaridis, et al.
- 1191** ■ **BRIEF COMMUNICATION. SUV_{max} Above 20 in ¹⁸F-FDG PET/CT at Initial Diagnostic Workup Associates with Favorable Survival in Patients with Cancer of Unknown Primary**
Gregor Zaun, Manuel Weber, Martin Metzenmacher, Marcel Wiesweg, Thomas Hilser, Yasmin Zaun, Sven Liffers, Michael Pogorzelski, Isabel Virchow, Wilfried Eberhardt, et al.

Basic

- 1195** ■ **FEATURED BASIC SCIENCE ARTICLE. Metformin-Induced Receptor Turnover Alters Antibody Accumulation in HER-Expressing Tumors**
Sandeep Surendra Panikar, Nai Keltee, Na-Keysha Berry, Shayla Shmuel, Zachary T. Fisher, Emma Brown, Abbey Zidel, Alex Mabry, and Patricia M.R. Pereira
- 1203** **Pretargeting with Cucurbituril-Adamantane Host-Guest Pair in Xenograft Models**
Vilma I.J. Jallinoja, Courtney H. Abbriano, Kavita Bhatt, Amritjyot Kaur, David J. Schlyer, Paul J. Yazaki, Brandon D. Carney, and Jacob L. Houghton

THERANOSTICS

Clinical

- 1210** **Clinical Evaluation of ⁶⁸Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin $\alpha_v\beta_3$ in Various Cancer Types**
Liang Zhao, Xuejun Wen, Weizhi Xu, Yizhen Pang, Long Sun, Xiaoming Wu, Pengfei Xu, Jingjing Zhang, Zhide Guo, Qin Lin, et al.

- 1218** **Evaluation of the Diagnostic Accuracy of FAPI PET/CT in Oncologic Studies: Systematic Review and Metaanalysis**

Grayson Wass, Kari Clifford, and Rathan M. Subramaniam

- 1225** **Initial Evaluation of [¹⁸F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions**

Tadashi Watabe, Sadahiro Naka, Mitsuki Tatsumi, Takashi Kamiya, Toru Kimura, Yasushi Shintani, Kaori Abe, Tomohiro Miyake, Kenzo Shimazu, Shogo Kobayashi, et al.

- 1232** **Tumor Characterization by [⁶⁸Ga]FAPI-46 PET/CT Can Improve Treatment Selection for Pancreatic Cancer Patients: An Interim Analysis of a Prospective Clinical Trial**

Pawel Rasinski, Siri af Burén, Maria Holstensson, Ted Nilsson, Louiza Loizou, Thuy A. Tran, Ernesto Sparrelied, J. Matthias Löhr, and Rimma Axelsson

- 1238** **The Diagnostic Value of PSMA PET/CT in Men with Newly Diagnosed Unfavorable Intermediate-Risk Prostate Cancer**

Marinus J. Hagens, Wietske I. Luining, Auke Jager, Maarten L. Donswijk, Zing Cheung, Maurits Wondergem, Daniela E. Oprea-Lager, André N. Vis, Pim J. van Leeuwen, and Henk G. van der Poel

- 1244** **Safety and Efficacy of [¹⁷⁷Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years**

Robert Tauber, Karina Knorr, Margitta Retz, Isabel Rauscher, Sonia Grigorascu, Kimberley Hansen, Calogero D'Alessandria, Hans-Jürgen Wester, Jürgen Gschwend, Wolfgang Weber, et al.

- 1252** **The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy**

Amir Karimzadeh, Matthias Heck, Robert Tauber, Esteban Solaris, Stephan Nekolla, Karina Knorr, Bernhard Haller, Calogero D'Alessandria, Wolfgang A. Weber, Matthias Eiber, et al.

- 1259** **A VISION Substudy of Reader Agreement on ⁶⁸Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for ¹⁷⁷Lu-PSMA-617 Radioligand Therapy**

Phillip H. Kuo, Don C. Yoo, Ryan Avery, Marc Seltzer, Jeremie Calais, James Nagarajah, Wolfgang A. Weber, Wolfgang P. Fendler, Michael S. Hofman, Bernd J. Krause, et al.

- 1266** **[¹⁷⁷Lu]Lu-PSMA-Radioligand Therapy Efficacy Outcomes in Taxane-Naïve Versus Taxane-Treated Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Metaanalysis**

Swayamjeet Satapathy, Ranjit K. Sahoo, and Chandrasekhar Bal

- 1272** **Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy**

Philipp E. Hartrampf, Patrick W. Mihatsch, Anna Katharina Seitz, Lilja B. Solnes, Steven P. Rowe, Martin G. Pomper, Hubert Kübler, Thorsten A. Bley, Andreas K. Buck, and Rudolf A. Werner

CARDIOVASCULAR

Clinical

1279 ■ FEATURED ARTICLE OF THE MONTH. Molecular Imaging of Myocardial Fibroblast Activation in Patients with Advanced Aortic Stenosis Before Transcatheter Aortic Valve Replacement: A Pilot Study

Johanna Diekmann, Jonas Neuser, Manuel Röhrich, Thorsten Derlin, Carolin Zwadlo, Tobias Koenig, Desiree Weiberg, Felix Jäckle, Tibor Kempf, Tobias L. Ross, et al.

INFECTIOUS DISEASE

Clinical

1287 Importance of Blood Glucose Management Before ^{18}F -FDG PET/CT in 322 Patients with Bacteremia of Unknown Origin

Jordy P. Pijl, Andor W.J.M. Glaudemans, Olivier Gheysens, Riemer H.J.A. Slart, and Thomas C. Kwee

RADIOBIOLOGY/DOSIMETRY

Clinical

1295 ■ SPECIAL CONTRIBUTION. MIRD Pamphlet No. 28, Part 2: Comparative Evaluation of MIRDcalc Dosimetry Software Across a Compendium of Diagnostic Radiopharmaceuticals

Lukas M. Carter, Juan C. Ocampo Ramos, Edmond A. Olguin, Justin L. Brown, Daniel Lafontaine, Derek W. Jokisch, Wesley E. Bolch, and Adam L. Kesner

AI/ADVANCED IMAGE ANALYSIS

Clinical

1304 Facial Anonymization and Privacy Concerns in Total-Body PET/CT

Aaron R. Selfridge, Benjamin A. Spencer, Yasser G. Abdelhafez, Keisuke Nakagawa, John D. Tupin, and Ramsey D. Badawi

MOLECULAR IMAGING

Clinical

1310 ■ BRIEF COMMUNICATION. Endogenous Opioid Release After Orgasm in Man: A Combined PET/Functional MRI Study
Patrick Jern, Jinglu Chen, Jouni Tuisku, Tiina Saanijoki, Jussi Hirvonen, Lasse Lukkarinen, Sandra Manninen, Semi Helin, Vesa Putkinen, and Lauri Nummenmaa

Basic

1314 Comparative Evaluation of [^{18}F]5-Fluoroaminosuberlic Acid and (4S)-4-3-[^{18}F]fluoropropyl)-L-Glutamate as System \times_{C}^{-} -Targeting Radiopharmaceuticals

Milena Colovic, Hua Yang, Lily Southcott, Helen Merckens, Nadine Colpo, Francois Bénard, and Paul Schaffer

ILLUSTRATED POST

Clinical

1322 ^{161}Tb -PSMA Radioligand Therapy: First-in-Humans SPECT/CT Imaging

Akram Al-Ibraheem, Rahma M. Doudeen, Diyaa Juaidi, Alaa Abufara, and Stephan Maus

LETTERS TO THE EDITOR

1324 Radiopharmaceutical Extravasations Can Have Consequences

Dale L. Bailey

1324 Reply. Radiopharmaceutical Extravasations Can Have Consequences

Ashwin Singh Parihar, Lisa Raymond-Schmidt, John P. Crandall, Farrokh Dehdashti, and Richard L. Wahl

1326 PSMA Is Not Specific to Prostate Cancer

Loic Ah-Thiane, Ludovic Ferrer, and Caroline Rousseau

1326 Reply. PSMA Is Not Specific to Prostate Cancer

Susan Notohamiprodjo, Matthias Eiber, Christian Lohrmann, and Wolfgang A. Weber

DEPARTMENTS

6A This Month in JNM